{
  "title": "Peptide Therapeutics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)",
  "slug": "peptide-therapeutics-market",
  "industry": "Pharmaceuticals & Therapeutics",
  "parent_industry": "Healthcare (Pharma, Medical Devices, Biotech)",
  "url": "https://www.mordorintelligence.com/industry-reports/peptide-therapeutics-market",
  "scraped_at": "2026-09-17T17:43:56+07:00",
  "dataset_properties": [
    {
      "@type": "PropertyValue",
      "name": "Market Size (2026)",
      "value": 49.68,
      "unitText": "USD Billion"
    },
    {
      "@type": "PropertyValue",
      "name": "Market Size (2031)",
      "value": 70.2,
      "unitText": "USD Billion"
    },
    {
      "@type": "PropertyValue",
      "name": "Growth Rate (2026 - 2031)",
      "value": 7.16,
      "unitText": "PERCENT"
    },
    {
      "@type": "PropertyValue",
      "name": "Fastest Growing Market",
      "value": "Asia Pacific"
    },
    {
      "@type": "PropertyValue",
      "name": "Largest Market",
      "value": "North America"
    },
    {
      "@type": "PropertyValue",
      "name": "Market Concentration",
      "value": "Medium"
    }
  ],
  "faq": [
    {
      "@type": "Question",
      "name": "How large is the peptide therapeutics market in 2026 and what is its expected value by 2031?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The peptide therapeutics market size is USD 49.68 billion in 2026 and is projected to reach USD 70.20 billion by 2031 at a 7.16% CAGR."
      }
    },
    {
      "@type": "Question",
      "name": "Which application area is growing fastest within peptide therapeutics?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Gastrointestinal disorders lead growth with an 11.85% CAGR through 2031, propelled by GLP-2 analogs such as apraglutide and glepaglutide."
      }
    },
    {
      "@type": "Question",
      "name": "Why are recombinant expression systems gaining share in peptide manufacturing?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Recombinant expression lowers cost-of-goods by 30-50% for peptides longer than 40 amino acids and supports 10,000-liter fermentation scales, outpacing traditional SPPS cost structures."
      }
    },
    {
      "@type": "Question",
      "name": "What are the main restraints limiting oral peptide formulations?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Proteolytic degradation and low intrinsic permeability restrict oral bioavailability to about 1%, necessitating high doses or device-based delivery solutions that raise development costs."
      }
    },
    {
      "@type": "Question",
      "name": "How is trade policy influencing peptide manufacturing locations?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "U.S. tax credits and biosecurity legislation plus European on-shoring incentives are driving CDMOs like Lonza, Bachem, and Samsung Biologics to expand capacity in North America and Europe."
      }
    }
  ],
  "images": [
    "images/peptide-therapeutics-market-size.png",
    "images/peptide-therapeutics-market-major-players.png",
    "images/peptide-therapeutics-market-share-by-marketing-type.png",
    "images/peptide-therapeutics-market-share-by-technology.png",
    "images/peptide-therapeutics-market-growth-rate-by-region.png",
    "images/peptide-therapeutics-market-competitive-landscape-market-concentration.png",
    "images/market-snapshot.png",
    "images/Esomar-25.png",
    "images/GPTW-25-3xl.png",
    "images/peptide-therapeutics-market-size.png"
  ],
  "sections_count": 14
}